Oxford Biodyn Regulatory News (OBD)

Oxford BioDynamics Plc

Board change

Oxford, UK - 30 December 2020 - Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch™ 3D genomics platform, announces that Christian Hoyer Millar will retire from the Board of Directors on 31 December 2020.

Christian co-founded OBD along with Dr Alexandre Akoulitchev and Dr Aroul Ramadass in 2008 and as CEO was instrumental in helping to develop the Company into a best-in-class global 3D Genomics innovator.

Earlier this year, he brought in his successor as CEO, Dr Jon Burrows and moved to an Executive Director role. Christian has been a major force in championing OBD's technology and the strong ties it has built with big pharma and academia. Without his involvement the Company would not have the exceptional platform for future growth and commercialization that it does today.

Dr. Jon Burrows, CEO of Oxford BioDynamics commented: "Christian has done a marvelous job at OBD and will be missed. During his tenure, the EpiSwitch™ platform has been proven and we are all immensely excited about the Company's future. On behalf of the Company, I wish him and his family all the best for the future".

Christian Hoyer Millar said, "I leave OBD, at a time where it is uniquely positioned to drive the commercialization and application of its platform technology. I wish Jon and all my former colleagues at the Company the very best for the future."

-Ends-

For further details please contact:

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch™, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases. 

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial team in the US and a reference laboratory in Penang, Malaysia

For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow on Twitter or LinkedIn.

About EpiSwitch™

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch™ can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch™ is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch™ data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

Oxford BioDynamics is leveraging its leading technology to develop a pipeline of tests in a wide range of indications, such as Covid-19 severity, immuno-oncology, neurodegenerative and autoimmune diseases.